Macaulay V.M., Lord S., Hussain S., Maroto J.P., Jones R.H., Climent M.Á., Cook N., Lin, CC, Wang, SS, Bianchini D., Bailey M., Schlieker L., Bogenrieder T., de Bono J.. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6)DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6.400(Q1/2D).

Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).

Grunwald, V, Powles, T, Kopyltsov, E, Kozlov, V, Alonso-Gordoa, T, Eto, M, Hutson, T, Motzer, R, Winquist, E, Maroto, P, Keam, B, Procopio, G, Wong, SR, Melichar, B, Rolland, F, Oya, M, Rodriguez-Lopez, K, Saito, K, McKenzie, J, Porta, C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4)DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8.300(Q1/1D).

Mayayo-Vallverdu, C, de Heredia, ML, Prat, E, Gonzalez, L, Guarch, ME, Vilches, C, Munoz, L, Asensi, MA, Serra, C, Llebaria, A, Casado, M, Artuch, R, Garrabou, G, Garcia-Roves, PM, Pallardo, FV, Nunes, V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10.700(Q1/1D).

Canto, E, Anguera, G, Jimenez, N, Mellado, B, Ramirez, O, Mariscal, A, Maroto, P, Vidal, S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13)DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3.000(Q1/2D).

Giménez-Capitán A., Sánchez-Herrero E., de Lope, LR, Aguilar-Hernández A., Sullivan I., Calvo V., Moya-Horno I., Viteri S., Cabrera C., Aguado C., Armiger N., Valarezo J., Mayo-de-las-Casas C., Reguart N., Rosell R., Provencio M., Romero A., Molina-Vila M.A.. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9)DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5.000(Q1/3D).

Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, T, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03229-y. PMID:37273149. IF:2.800(Q2/5D).

Tsuboi M., Herbst R.S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J.W., Lu S., Su, WC, De Marinis F., Shepherd F.A., Lee K.H., Le N.T., Dechaphunkul A., Kowalski D., Poole L., Bolanos A., Rukazenkov Y., Wu, YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2)DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96.300(Q1/1D).

de Velasco G., Alonso-Gordoa T., Rodríguez-Vida A., Anguera G., Campayo M., Pinto Á., Ortega E.M., Gallardo E., Núñez N.F., García-Carbonero I., Reig O., Méndez-Vidal M.J., Fernández-Calvo O., Cassinello N.V., Torregrosa D., López-Martín A., Rosero A., Valiente P.G., de España C.G., Climent M.A., Santasusana M.D., Sánchez Á.R., González I.C., Afonso R., García del Muro X., Casinello J., Fernández-Parra E.M., García Sánchez L., Afonso J., Polo S.H., Asensio Ú.. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3)DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2.300(Q2/5D).

Roldan-Romero, JM, Valdivia, C, Santos, M, Lanillos, J, Maroto, P, Anguera, G, Calsina, B, Martinez-Montes, A, Monteagudo, M, Mellid, S, Leandro-Garcia, LJ, Montero-Conde, C, Cascon, A, Roncador, G, Coloma, J, Robledo, M, Rodriguez-Antona, C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6)DOI:10.1002/ijc.34575. PMID:37260183. IF:5.700(Q1/2D).

Kobel, M, Kang, EY, Weir, A, Rambau, PF, Lee, CH, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, YJ, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Cajal, TRY, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, MT, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3)DOI:10.1002/cjp2.311. PMID:36948887. IF:3.400(Q1/3D).

Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Fournier, B, Dingemans, AMC, Dziadziuszko, R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5)DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56.700(Q1/1D).

Lozano, R, Castro, E, -Campos, FL, Thorne, H, Ramirez-Backhaus, M, Aragon, IM, Cendon-Florez, Y, Gutierrez-Pecharroman, A, Salles, DC, Romero-Laorden, N, Lorente, D, Gonzalez-Peramato, P, Calatrava, A, Alonso, C, Anido, U, Arevalo-Lobera, S, Balmana, J, Chirivella, I, Juan-Fita, MJ, Llort, G, Cajal, TRY, Almagro, E, Alameda, D, Lopez-Casas, PP, Herrera, B, Mateo, J, Pritchard, CC, Antonarakis, ES, Lotan, TL, Rubio-Briones, J, Sandhu, S, Olmos, D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7.600(Q1/2D).

Sanfilippo, R, Hindi, N, Jurado, JC, Blay, JY, Lopez-Pousa, A, Italiano, A, Alvarez, R, Gutierrez, A, Rincon-Perez, I, Sangalli, C, Aguiar, JLP, Romero, J, Morosi, C, Sunyach, MP, Fabbroni, C, Romagosa, C, Ranchere-Vince, D, Dei Tos, AP, Casali, PG, Martin-Broto, J, Gronchi, A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5)DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22.300(Q1/1D).

Martinez-Bosch, N, Vilarino, N, Alameda, F, Mojal, S, Arumi-Uria, M, Carrato, C, Aldecoa, I, Ribalta, T, Vidal, N, Bellosillo, B, Menendez, S, Del Barco, S, Gallego, O, Pineda, E, Lopez-Martos, R, Hernandez, A, Mesia, C, Esteve-Codina, A, de la Iglesia, N, Balana, C, Martinez-Garcia, M, Navarro, P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6)DOI:10.3390/cells12060843. PMID:36980184. IF:5.100(Q2/4D).

Chmielecki, J, Gray, JE, Cheng, Y, Ohe, Y, Imamura, F, Cho, BC, Lin, MC, Majem, M, Shah, R, Rukazenkov, Y, Todd, A, Markovets, A, Barrett, JC, Hartmaier, RJ, Ramalingam, SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14.700(Q1/1D).

Blay J.Y., Hindi N., Bollard J., Aguiar S., Jr., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Caro-Sánchez C.H.S., Carvajal B., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden V., Chacón M., Clara M., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., dei Tos A.P., Dominguez Malagon H.R., Donati D., Dufresne A., Eriksson M., Farias-Loza M., Fernandez P., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gelderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes David B.B., Lopez-Pousa A., Lutter G., Martinez-Said H., Martinez-Tlahuel J., Mello C.A., Morales Pérez J.M., Moura David S., Nascimento A.G., Ortiz-Cruz E.J., Palmerini E., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Salas R., Santos T.T.G., Scotlandi K., Soule T., Stacchiotti S., Valverde C., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312)). CANCER TREATMENT REVIEWS. 2023; 115DOI:10.1016/j.ctrv.2023.102523. PMID:36796283. IF:9.600(Q1/1D).

Pilcher, L, Pahlke, S, Urquhart, O, O'Brien, KK, Dhar, V, Fontana, M, Gonzalez-Cabezas, C, Keels, MA, Mascarenhas, AK, Nascimento, MM, Platt, JA, Sabino, GJ, Slayton, RL, Tinanoff, N, Young, DA, Zero, DT, Tampi, MP, Purnell, D, Salazar, J, Megremis, S, Bienek, D, Carrasco-Labra, A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2)DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3.100(Q1/2D).

Trilla-Fuertes L., Gámez-Pozo A., Prado-Vázquez G., López-Vacas R., Zapater-Moros A., López-Camacho E., Lumbreras-Herrera M.I., Soriano V., Garicano F., Lecumberri M.J., de la Borbolla, MR, Majem M., Pérez-Ruiz E., González-Cao M., Oramas J., Magdaleno A., Fra J., Martín-Carnicero A., Corral M., Puértolas T., Ramos R., Vara, JAF, Espinosa E.. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010801. PMID:36614248. IF:4.900(Q1/3D).

Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N., Tarruella, MM, Casas-Martin J., Tsourti Z., Marti N., Kammler R., Danson S., O'Brien M., Stahel R.A.. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4.500(Q1/2D).